A recent randomized controlled trial of lopinavir and ritonavir in severe COVID-19 reported that elevated levels of AST, ALT and total bilirubin occurred as adverse effects in a few patients.41 Another case series from Wuhan reported that 55.4% of patients experienced liver injuries after treatment with lopinavir and ritonavir.26 Fan et al. The gene discussed is GPT; the disease is COVID-19.